Cough Hypersensitivity Syndrome Market Report 2026

Cough Hypersensitivity Syndrome Market Overview

• Cough Hypersensitivity Syndrome market size has reached to $10.92 billion in 2025 • Expected to grow to $15.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Growing Prevalence Of Chronic Respiratory Diseases Boosts The Cough Hypersensitivity Syndrome Market • Market Trend: Advancements In Cough Hypersensitivity Syndrome Care • North America was the largest region in 2025.

What Is Covered Under Cough Hypersensitivity Syndrome Market?

Cough hypersensitivity syndrome (CHS) is a medical condition characterized by an exaggerated and abnormal response of the cough reflex to various stimuli, often leading to persistent and chronic coughing. It is commonly associated with conditions such as asthma, gastroesophageal reflux disease (GERD) and upper airway disorders. The main drug types of cough hypersensitivity syndrome are inhaled corticosteroids, antitussive agents, short-acting beta-2 agonists, anticholinergics, proton pump inhibitors, antihistamines and others. Inhaled corticosteroids (ICS) refer to a class of medications used in the treatment of various respiratory conditions. The various route of administration includes oral, inhalation and others, used by various end-users such as hospitals, specialty clinics, homecare and others.

What Is The Cough Hypersensitivity Syndrome Market Growth Forecast?

The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $15.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in cough pathway research, development of novel antitussive drugs, increasing specialist referrals, improved diagnostic protocols, growing chronic respiratory disease burden. Major trends in the forecast period include growing focus on chronic cough diagnosis, increased use of targeted pharmacological therapies, rising awareness of cough reflex disorders, expansion of specialty respiratory clinics, integration of multidisciplinary treatment approaches.

Global Cough Hypersensitivity Syndrome Market Segmentation

1) By Drug Class: Inhales Corticosteroids, Antitussive Agents, Short-Acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Other Drugs 2) By Route Of Administration: Oral, Inhalation, Other Route Of Administrations 3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Inhaled Corticosteroids: Budesonide, Fluticasone, Beclomethasone 2) By Antitussive Agents: Dextromethorphan, Codeine, Benzonatate 3) By Short-Acting Beta-2 Agonists: Albuterol, Levalbuterol 4) By Anticholinergics: Ipratropium Bromide, Tiotropium 5) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Lansoprazole 6) By Antihistamines: Cetirizine, Loratadine, Diphenhydramine 7) By Other Drugs: Mucolytics, Combination Therapy Drugs

What Is The Driver Of The Cough Hypersensitivity Syndrome Market?

The rising prevalence of chronic respiratory diseases is expected to propel the growth of the cough hypersensitivity syndrome market going forward. Chronic respiratory diseases (CRDs) refer to a group of long-term diseases that affect the airways and lungs, leading to persistent breathing difficulties and reduced lung function over time. Cough hypersensitivity syndrome treatment reduces discomfort, enhances respiratory health, thereby improving the quality of life for patients suffering from chronic respiratory diseases such as asthma. For instance, in March 2025, according to Australian Bureau of Statistics, an Australian-based government administration, in December 2024, there were 222 doctor-certified deaths due to COVID-19, an increase from 135 in October and 186 in November. Therefore, the rising prevalence of chronic respiratory diseases drives the cough hypersensitivity syndrome industry.

Key Players In The Global Cough Hypersensitivity Syndrome Market

Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd, Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.

Global Cough Hypersensitivity Syndrome Market Trends and Insights

Major companies operating in the cough hypersensitivity syndrome market are focused on advancing asthma treatment pipelines such as asthma rescue inhalers to enhance patient outcomes and improve overall quality of life. Asthma rescue inhalers are portable devices delivering fast-acting medication to open airways quickly. It may help alleviate sudden coughing episodes by temporarily reducing airway sensitivity and providing relief from cough-related airway obstruction. For instance, in April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Launch Therapeutics, a US-based clinical development company. This partnership aims to accelerate the clinical research program for its ICS-SABA (inhaled corticosteroid and short-acting beta-agonist) inhaler, TEV-‘248. This inhaler combines fluticasone propionate and albuterol sulfate, targeting both adult and pediatric asthma patients. Additionally, it aims to reduce reliance on generics.

What Are Latest Mergers And Acquisitions In The Cough Hypersensitivity Syndrome Market?

In June 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company that manufactures drugs for cough hypersensitivity syndrome, acquired Bellus Health Inc. for $2.0 billion. With this acquisition, GSK aims to strengthen its portfolio of respiratory medications, research and development (R&D), production and commercialization capabilities. Bellus Health Inc. is a Canada-based biotech company that develops drugs for cough hypersensitivity syndrome.

Regional Outlook

North America was the largest region in the cough hypersensitivity syndrome market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cough Hypersensitivity Syndrome Market?

The cough hypersensitivity syndrome market consists of sales of cough suppressants, steam inhalers and humidifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cough Hypersensitivity Syndrome Market Report 2026?

The cough hypersensitivity syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cough hypersensitivity syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.